Amarantus BioScience is focused on developing certain biologics surrounding the intellectual property and proprietary technologies the company owns to treat and/or diagnose Parkinson’s disease, traumatic brain injury, ischemic heart disease, and other human diseases. Amarantus owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”) and is developing MANF-based products as treatments for brain disorders. For more information visit the company’s Web site at www.amarantus.com
Let us hear your thoughts below: